Model Introduction
The MODY2 (Maturity-Onset Diabetes of the Young, Type 2) animal model is primarily constructed using genetic engineering. The core principle involves utilizing gene knockout technology to inactivate the glucokinase (GCK) gene in the livers of experimental mice. Since GCK is the first key enzyme in the glucose metabolism pathway in hepatocytes and pancreatic β-cells, it plays a vital regulatory role in maintaining blood glucose homeostasis. A reduction in its activity leads to pathological changes similar to human MODY, specifically diabetes triggered by impaired hepatic glucose sensing and metabolic dysfunction.
Research Applications
This model is mainly used to simulate the occurrence and development of human MODY2 diabetes. It aims to elucidate the pathogenesis of this type of diabetes at the genetic and molecular levels and serves as a biomedical research platform for screening therapeutic drugs targeting GCK activity abnormalities.
Key Points of Experimental Design
- Modeling Method: Preparation of liver-specific GCK-deficient (GCK -/-) mouse models using gene knockout technology.
- Experimental Subject: Mice.
- Observation Period: Experimental records indicate the need for long-term follow-up; a clear phenotypic node is at 6 weeks of age.
- Modeling Mechanism: Artificial reduction of hepatocyte GCK activity to simulate metabolic disorders caused by monogenic mutations.
Key Monitoring Indicators
- Blood Glucose Levels: Monitoring fasting blood glucose; fasting blood glucose in 6-week-old model mice should be significantly higher than that of the control group.
- Glucose Tolerance: Performing glucose tolerance tests (OGTT/IPGTT); model mice exhibit impaired glucose tolerance.
- Enzyme Activity Assay: Evaluating the activity levels of GCK within hepatocytes.
- Time-dimensional Indicators: Observing the trend of blood glucose gradually increasing with age.
